Harrow Launches 'Vevye Access for All' to Reduce Patient Barriers for Dry Eye Disease Treatment

Harrow announced 'Vevye Access For All' – a new initiative that aims to reduce patient barriers to dry eye disease treatment. Harrow partnered with specialty pharmacy PhilRx to offer Vevye (cyclosporine ophthalmic solution) 0.1% for eligible patients at $59 a bottle. The goal is to offer patients the ability to start affordable treatment without delays in care, according to Harrow.

“For too long, patients, doctors, and pharmaceutical companies have been at the mercy of unseen middlemen who act as access gatekeepers, using needless red tape to prevent patients from benefitting from medications they are prescribed,” Mark L. Baum, Chief Executive Officer of Harrow, said in a recent press release. “This program puts power back where it belongs – in the hands of eyecare professionals and their patients – by simplifying the prescribing and dispensing process and removing access impediments for all patients, creating a more frictionless path to therapy.”

Additional key benefits of the program include no required prior authorizations, no delay prescription processing, and a money-back guarantee.

Many eye care providers state that this is an important step in giving their patients greater access to care, said Ranjan P. Malhotra, MD, a board-certified ophthalmologist with St. Louis-based Ophthalmology Associates. “As a cornea and refractive surgeon, I understand how critical a healthy ocular surface is to achieving superior surgical outcomes. With Vevye Access For All, I can confidently prescribe Vevye, knowing that my patients can start treatment quickly and at a price they can afford – without the burden of the growing number of insurance hurdles.”

Vevye Access For All is available across the country starting today. Physicians that would like to enroll their patients in the program should send Vevye prescriptions to PhilRx via their electronic medical records, and eligible patients will receive the discounted pricing and benefits through the pharmacy. Looking ahead, Harrow states they aspire to make this program available at all pharmacies nationwide.